With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
|Articles|April 19, 2021
Pharmacy Times: Week of April 19 Lineup
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.
Advertisement
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week, including:
- A video interview with Nick Sinagra, spinal muscular atrophy patient, about his treatment journey and experiences with 2 different SMA treatments.
- An article that highlights a new study measuring the impact of integrated specialty pharmacy services on the total cost of health care. Conducted by Shields Health Solutions in conjunction with Optum Advisory Services, the study found that risk-adjusted per member per month costs were 13% lower for the intervention group compared to the control group.
Advertisement
Related to this article
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Findings presented at the European Respiratory Society Congress 2026 suggest semaglutide may offer respiratory benefits beyond its approved diabetes and obesity indications.
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disorder that primarily affects the nervous system, causing progressive loss of muscle control and coordination.
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Most patients screened by a hospital pharmacist-led transitions-of-care service had unmet pneumococcal and other vaccine needs, and most accepted vaccination when offered.
The data helps pharmaicts predict who will react strongly to mRNA vaccines—giving them a science-backed talking point during respiratory season.
CDC-recommended adult vaccination programs for pneumococcal disease, RSV, influenza, and COVID-19 prevent over 182,000 deaths and generate up to $12 in societal value for every $1 spent.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
4
Ambulatory Pharmacists Convene in Boston at NEIAP's 2026 Annual Forum
5